A number of stocks fell in the morning session after the Trump administration's announcement of new global tariffs reignited ...

The latest update pegs Pacific Biosciences of California’s fair value at US$2.50 per share, compared with the prior US$2.42 anchor, giving investors a fresh reference point for the story. Analysts are ...

MENLO PARK, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will participate ...

Retrotransposons are pivotal in human genome evolution, driving structural variation and regulatory innovation while influencing health and disease.

ArgenTag joins PacBio to enable instrument-free single-cell kits to support long-read isoform sequencing at single-cell ...

ArgenTag have joined PacBio’s Compatible Partner Program and opened a grant to provide access to single-cell sequencing tech.

SANTA CLARA, CA, UNITED STATES, January 20, 2026 /EINPresswire.com/ -- OmicInsight Corporation, an innovator in ...

The transition from testing the dead to testing the living is the latest example of how genomics is expanding horizons for ...

Flax (Linum usitatissimum L.) is one of the richest plant sources of alpha-linolenic acid, an essential omega-3 fatty acid ...

PACB beats Q4 estimates as revenue jumps 14%, gross margin hits 41% and 2026 revenues are projected in the range of $165-$180M after strategic moves.

Genomics company Pacific Biosciences of California (NASDAQ:PACB) reported Q4 CY2025 results topping the market’s revenue ...

Good afternoon, and welcome to PacBio's Fourth Quarter and Full Year 2025 Earnings Conference Call. Earlier today, we issued a press release outlining the financial results we'll be discussing on ...